|
gptkbp:instanceOf
|
combination drug
inhaler
|
|
gptkbp:activeIngredient
|
gptkb:budesonide
gptkb:formoterol
|
|
gptkbp:approvedBy
|
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
|
|
gptkbp:ATCCode
|
gptkb:R03AK07
|
|
gptkbp:contraindication
|
hypersensitivity to budesonide
hypersensitivity to formoterol
|
|
gptkbp:countryOfOperation
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:drugClass
|
gptkb:Corticosteroid
long-acting beta2-agonist
|
|
gptkbp:form
|
dry powder inhaler
160/4.5 mcg
320/9 mcg
80/4.5 mcg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Symbicort Turbuhaler
|
|
gptkbp:manufacturer
|
gptkb:AstraZeneca
|
|
gptkbp:marketedAs
|
2000s
|
|
gptkbp:mechanismOfAction
|
reduces inflammation and relaxes airway muscles
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
inhalation
|
|
gptkbp:sideEffect
|
headache
tremor
oral thrush
hoarseness
palpitations
|
|
gptkbp:storage
|
store below 30°C
|
|
gptkbp:usedFor
|
asthma
chronic obstructive pulmonary disease
|
|
gptkbp:bfsParent
|
gptkb:Symbicort
|
|
gptkbp:bfsLayer
|
6
|